Compare Amgen, Inc. (AMGN) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs PayPal Holdings, Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while PayPal Holdings, Inc. trades at $46.33 (market cap $40.86B). The key difference: Amgen, Inc. is far larger — about 4.8× PayPal Holdings, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | PYPL | |
|---|---|---|
Market Cap | $196.12B | $40.86B |
Sector | Health | Financials |
52-Week High | $388.16 | $78.22 |
52-Week Low | $271.18 | $39.08 |
Enterprise Value | $241.41B | $40.93B |
Dividend Yield | 2.77% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
PayPal (PYPL) trades at $46.32, up 2.21% today, with a bullish technical signal and strong fundamentals including a low P/E of 8.69 and robust net income margin of 15%. Recent earnings beat expectations in Q1 2026, and the company is targeting $1.5B in AI-driven savings to fuel growth. The stock is near resistance at $46, with support at $44.
PYPL presents a value opportunity with attractive valuation multiples and steady revenue growth, but faces competition and margin pressure. Analyst consensus is mixed with a $48.36 price target, indicating modest upside. Risks include execution challenges and macroeconomic headwinds, yet strong cash flow supports shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
